Matt Augustson - Lifecore Biomedical Senior Technology
| LFCR Stock | 5.76 0.16 2.86% |
Executive
Matt Augustson is Senior Technology of Lifecore Biomedical
| Address | 3515 Lyman Boulevard, Chaska, MN, United States, 55318 |
| Phone | (952) 368-4300 |
| Web | https://www.lifecore.com |
Lifecore Biomedical Management Efficiency
The company has return on total asset (ROA) of (0.0247) % which means that it has lost $0.0247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2958) %, meaning that it created substantial loss on money invested by shareholders. Lifecore Biomedical's management efficiency ratios could be used to measure how well Lifecore Biomedical manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/26/2025, Return On Tangible Assets is likely to drop to -0.02. In addition to that, Return On Capital Employed is likely to drop to 0.01. At this time, Lifecore Biomedical's Non Currrent Assets Other are relatively stable compared to the past year. As of 02/26/2025, Other Assets is likely to grow to about 25.1 M, while Total Assets are likely to drop slightly above 248.7 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mitchell Gendel | Tilray Inc | 58 | |
| Michael MD | Ironwood Pharmaceuticals | 66 | |
| Boris Gorelik | Kamada | 44 | |
| Randy Daigneau | Tilray Inc | N/A | |
| Amir London | Kamada | 56 | |
| Chris Bitterman | Cumberland Pharmaceuticals | 60 | |
| Jean Marstiller | Cumberland Pharmaceuticals | 75 | |
| Elizabeth Geary | Ironwood Pharmaceuticals | N/A | |
| Jon Knight | Kamada | 59 | |
| Timothy CPA | Shuttle Pharmaceuticals | 66 | |
| Mitchell JD | Tilray Inc | 59 | |
| Mike Nanfito | Ironwood Pharmaceuticals | N/A | |
| Andrew Zwible | Journey Medical Corp | N/A | |
| BA MA | Akanda Corp | 74 | |
| Erin Gull | Cumberland Pharmaceuticals | N/A | |
| Jana Noeldeke | Ironwood Pharmaceuticals | N/A | |
| Andrew Davis | Ironwood Pharmaceuticals | 38 | |
| Berrin Noorata | Tilray Inc | N/A | |
| Chaime Orlev | Kamada | 55 | |
| Nyree Pinto | Tilray Inc | N/A | |
| Tammi Gaskins | Ironwood Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0247 |
Lifecore Biomedical Leadership Team
Elected by the shareholders, the Lifecore Biomedical's board of directors comprises two types of representatives: Lifecore Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lifecore. The board's role is to monitor Lifecore Biomedical's management team and ensure that shareholders' interests are well served. Lifecore Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lifecore Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Darren Hieber, Senior Partnerships | ||
| Parker Javid, Vice President | ||
| Matt Augustson, Senior Technology | ||
| Aaron Perlitsh, Director Officer | ||
| Thomas Guldager, Vice Operations | ||
| James Hall, President CEO | ||
| Kara Morley, Senior Resources | ||
| Brikkelle Thompson, Senior Resources | ||
| John Morberg, Executive CFO | ||
| Paul Josephs, CEO President | ||
| Steve Laninga, Vice Operations | ||
| Jackie Klecker, Executive GM | ||
| Kipling Thacker, VP Scientist | ||
| Ryan CPA, CFO Secretary | ||
| Albert Bolles, I Foods |
Lifecore Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lifecore Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0247 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.05) % | ||||
| Current Valuation | 329.23 M | ||||
| Shares Outstanding | 37.03 M | ||||
| Shares Owned By Insiders | 5.40 % | ||||
| Shares Owned By Institutions | 76.43 % | ||||
| Number Of Shares Shorted | 2.47 M | ||||
| Price To Book | 13.42 X |
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.